Phaseline

Companies › Hubei Bio-Pharmaceutical Industrial Technological Institute

Hubei Bio-Pharmaceutical Industrial Technological Institute: clinical trials, targets and expected readouts

4 active drug programs in 4 registered trials: 4 Phase 1; Oncology, Respiratory, Other, Immunology; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HW243040–Phase 1HealthyMay 2027
HW221043
KRAS inhibitor
–Phase 1Advanced Solid TumorsJun 2029
HW211026–Phase 1Actinic Keratosis (AK)–
HW241045–Phase 1Healthy Volunteers–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07318675HW211026Phase 1Actinic Keratosis (AK)ImmunologyMar 2026
NCT07448194HW241045Phase 1Healthy VolunteersRespiratoryJun 2026
NCT07737496HW243040Phase 1HealthyOtherMay 2027
NCT07719920HW221043Phase 1Advanced Solid TumorsOncologyJun 2029

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.